Gad-el-Mawia N, Mahmoud M, Osman A, El-Morsi B, El-Merzabani M M, Aboul-Enein M, Sakurai Y
Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):367-70.
A new drug, NSC-140117, was used in the management of 15 patients who had late bronchogenic carcinoma and were unable to receive surgical or radiotherapeutic treatment. Good responses in the form of 90% shrinkage in the size of the lesionswere encountered in nine patients (60%). Response is still being maintained from 6 months to 1.5 years after the start of therapy. No toxic effects, including hematopoietic toxicity, were encountered.
一种新药NSC - 140117被用于治疗15例晚期支气管源性癌患者，这些患者无法接受手术或放射治疗。9例患者（60%）出现了良好反应，表现为病灶大小缩小90%。治疗开始后6个月至1.5年，反应仍在维持。未出现包括造血毒性在内的毒性作用。
